Zelira Therapeutics Ltd. announced that it is entering the New Zealand market via a 5-year exclusive distribution agreement with NUBU Pharmaceuticals, New Zealand's largest medicinal cannabis distribution company. This distribution agreement expands the availability of Zenivol®, Zelira's clinically validated cannabinoid-based insomnia medication, beyond Australia and Germany, and HOPETM1 beyond Australia and the United States, into the highly regulated and tightly held New Zealand market, further expanding Zelira's global footprint for its Rx business. NUBU will be filing for formal New Zealand government registration with the Ministry of Health NZ for both Zenivol ® and HOPETM 1. Key terms of the distribution agreement include: Commencement date of 16 December, 2021 and a term of 5 years; Supply of finished dosages of Zenivol® and HOPETM 1 from Australia to New Zealand; NUBU will distribute products under the Zelira brand in New Zealand; To retain exclusivity, NUBU is required to purchase annual minimum quantities of Zenivol® and HOPETM 1 totalling over AUD 2.6 million (with AUD 178,000 in Year 1) for New Zealand over the 5-year term of the distribution agreement; As is usual in such agreements, the distribution agreement can be terminated when one party fails to perform by either party giving 30 days written notice.